Novo Nordisk within touching distance of European obesity market as CHMP recommends approval

The EU Committee for Medicinal Products for Human Use has recommended that Novo Nordisk's obesity drug Wegovy be approved. The pharmaceutical company expects to launch the product in Europe in the second half of 2022.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

Novo Nordisk has come one step closer to getting its obesity drug Wegovy approved in Europe, as the CHMP has recommended is approval.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading